Latent-state and model-based learning in PTSD.

Autor: Cisler JM; Department of Psychiatry and Behavioral Sciences, University of Texas at Austin, Austin, TX, USA; Institute for Early Life Adversity Research, University of Texas at Austin, Austin, TX, USA. Electronic address: josh.cisler@austin.utexas.edu., Dunsmoor JE; Department of Psychiatry and Behavioral Sciences, University of Texas at Austin, Austin, TX, USA; Institute for Early Life Adversity Research, University of Texas at Austin, Austin, TX, USA., Fonzo GA; Department of Psychiatry and Behavioral Sciences, University of Texas at Austin, Austin, TX, USA; Institute for Early Life Adversity Research, University of Texas at Austin, Austin, TX, USA., Nemeroff CB; Department of Psychiatry and Behavioral Sciences, University of Texas at Austin, Austin, TX, USA; Institute for Early Life Adversity Research, University of Texas at Austin, Austin, TX, USA.
Jazyk: angličtina
Zdroj: Trends in neurosciences [Trends Neurosci] 2024 Feb; Vol. 47 (2), pp. 150-162. Date of Electronic Publication: 2024 Jan 11.
DOI: 10.1016/j.tins.2023.12.002
Abstrakt: Post-traumatic stress disorder (PTSD) is characterized by altered emotional and behavioral responding following a traumatic event. In this article, we review the concepts of latent-state and model-based learning (i.e., learning and inferring abstract task representations) and discuss their relevance for clinical and neuroscience models of PTSD. Recent data demonstrate evidence for brain and behavioral biases in these learning processes in PTSD. These new data potentially recast excessive fear towards trauma cues as a problem in learning and updating abstract task representations, as opposed to traditional conceptualizations focused on stimulus-specific learning. Biases in latent-state and model-based learning may also be a common mechanism targeted in common therapies for PTSD. We highlight key knowledge gaps that need to be addressed to further elaborate how latent-state learning and its associated neurocircuitry mechanisms function in PTSD and how to optimize treatments to target these processes.
Competing Interests: Declaration of interests J.M.C. and J.E.D. have no competing interests to disclose. G.A.F., in the past 3 years, has served as a consultant to SynapseBio AI and Alto Neuroscience. He holds the following patent: Treatment of depression (US provisional patent 16/981,822). He is a stockholder in Alto Neuroscience. C.B.M., in the past 3 years, served as a consultant to AbbVie, ANeuroTech (division of Anima BV), Signant Health, Magstim, Inc., Intra-Cellular Therapies, Inc., EMA Wellness, Sage, Silo Pharma, Engrail Therapeutics, Pasithea Therapeutic Corp., EcoR1, GoodCap Pharmaceuticals, Inc., Senseye, Clexio, EmbarkBio, SynapseBio, and BioXcel Therapeutics. He is a stockholder with Seattle Genetics, Antares, Inc., Corcept Therapeutics Pharmaceuticals Company, EMA Wellness, Precisement Health, and Relmada Therapeutics. He has served on advisory boards for ANeuroTech (division of Anima BV), Brain and Behavior Research Foundation (BBRF), Anxiety and Depression Association of America (ADAA), Skyland Trail, Signant Health, Laureate Institute for Brain Research (LIBR), Inc., Heading Health, Pasithea Therapeutic Corp., and Sage. He has served on the Board of Directors for Gratitude America, Anxiety and Depression Association of America (ADAA), and Lucy Scientific Discovery, Inc. He holds the following patents: Method and devices for transdermal delivery of lithium (US 6375,990B1) and Method of assessing antidepressant drug therapy via transport inhibition of monoamine neurotransmitters by ex vivo assay (US 7148,027B2).
(Copyright © 2023 Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: